A novel algorithm shows that there is a robust network for transferring plasmids between bacteria which may be causing the rapid spread of antibiotic resistance.
List view / Grid view
Filter the results
Research has demonstrated that the Pfizer and BioNTech COVID-19 vaccine can neutralise the B.1.1.7 variant in pre-clinical studies.
The trial will primarily assess whether alisporivir (Debio 025) can significantly reduce COVID-19 viral load in hospitalised COVID-19 patients with moderate symptoms.
New research has said that clinical microbiology is critical to understanding COVID-19, with laboratories studying the coronavirus globally.
Update your blue dye ingress test and generate robust analytical CCI data in all stages of the product life cycle.
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
See how a leading biochemistry company implemented Real-time Microbial Monitoring to streamline process control in their water system.
Researchers studying the microbiologic diagnosis of pneumonia have identified ways to optimise a pneumonia panel.
The pilot study will determine whether an inhaled formulation of ensifentrine can expedite the recovery of patients hospitalised with COVID-19.
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.
Forty percent of neurofibromatosis type 1 patients enrolled in the trial had a >20 percent reduction in tumour burden with cabozantinib.